If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

在生物科技公司面临挑战的一年里，CRISPR Therapeutics AG的股票在更广泛的市场下跌中跌至52周低点，触及38.2美元。根据 InvestingPro 的数据，该公司保持"良好"的整体财务健康评分，其资产负债表显示现金多于债务，表现尤为强劲。这家以基因编辑开创性工作而闻名的公司，过去一年股价大幅回落38.23%。这一下跌反映了投资者对监管障碍、临床试验进度以及基因编辑疗法盈利能力的 ...

瑞士楚格和波士顿 - 目前股价为$39.69，市值33.9亿美元的CRISPR Therapeutics (NASDAQ:CRSP)宣布了其2025年战略重点，专注于继续推出其基因药物CASGEVY®以及几个关键开发项目的更新。公司以强劲的资产负债表开始新的一年，拥有约19亿美元的现金、现金等价物和可销售证券。根据 InvestingPro ...

Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...

Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...

Research from an Arizona State finance professor finds that most stocks over the long run don’t perform, but that a few ...

“With CRSP as the leading equities pricing data used by academic researchers, and OptionMetrics considered by many to be the ...

OptionMetrics and CRSP provide increased integration of U.S. equities and options data for use in academic research ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...